Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: A retrospective chart review

Aging Male

Volumn 11, Issue 4, 2008, Pages 157-161

  Curtis, Kelly K ^a   Adam, Terrence J ^a   Chen, Shu Chuan ^b   Pruthi, Rajiv K ^c   Gornet, Michael K ^c  

^a Department of Internal Medicine   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c Virginia Piper Cancer Center   (United States)

Author keywords

Anaemia; Androgen deprivation therapy; Metastatic prostate cancer; Symptoms

Indexed keywords

BICALUTAMIDE; GOSERELIN; HEMOGLOBIN; LEUPRORELIN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

AGED; AGING; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DETERIORATION; DISEASE SEVERITY; DRUG EFFECT; EXTERNAL BEAM RADIOTHERAPY; FISHER EXACT TEST; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MEDICAL RECORD REVIEW; METASTASIS; METASTATIC PROSTATE CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; STATISTICAL MODEL;

AGED; ANDROGEN ANTAGONISTS; ANEMIA; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; GOSERELIN; HEMOGLOBINS; HUMANS; LEUPROLIDE; LINEAR MODELS; MALE; NEOPLASM METASTASIS; NITRILES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS;

EID: 63249123610     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530802172438     Document Type: Article

References (19)

1. American Cancer Society: Cancer Facts and Figures. Available from: http://www.cancer.org/downloads/STT/CAFF2006PW Secured.pdf. Accessed 8 January 2006.
2. Beck JR, Kattan MV, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152:1894-1899.
3. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (GNRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. J Steroid Biochem 1985;123:833-841.
4. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66:1039-1044.
5. Eisenberger M, Crawford ED, McLeod D, et al. A comparison of leuprolide and flutamide vs leuprolide alone in newly diagnosed stage D2 prostate cancer: Prognostic and therapeutic importance of the minimal disease subset. Proc Am Soc Clin Oncol 1992;11:201.
6. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003; 44:209-214.
7. Hamilton JB. Role of testicular secretions as indicated by effects of castration in man and by studies of pathological conditions and short lifespan associated with maleness. Recent Prog Horm Res 1948;3:257-289.
8. Fonseca RS, Rajkumar V, White WL, et al. Anemia after orchiectomy. Am J Hematol 1998;59:230-233.
9. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 1991;36:190-194.
10. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 1994;152:448-452.
11. Strum SB, Tismag G. Anemia of androgen deprivation (AAD) in patients receiving combination hormone blockade: Response to erythropoietin. Proc Am Soc Clin Oncol 1994;13:238.
12. Asbell SO, Leon SA, Tester WJ, Brereton HD, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996;29:243-248.
13. Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999;83:43-46.
14. Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, et al. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 2003;23:1757-1762.
15. Qian L, Hua L, Wu H, Sui Y, et al. Anemia in patients on combined androgen block therapy for prostate cancer. Asian J Androl 2004;6:383-384.
16. Choo R, Chander S, Danjoux C, Morton G, et al. How are hemoglobin levels affected by androgen deprivation in nonmetastatic prostate cancer patients? Can J Urol 2005;12: 2547-2552.
17. Strum SB, McDermed JE, Scholz MC, Johnson H, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-941.
18. Oh WK. Anemia related to hormonal ablation therapy for prostate cancer. The Prostate Journal 2001;3:14-17.
19. Rodgers G, Cella D, Chanan-Khan A, Chesney C, et al. NCCN clinical practice guidelines in oncology. Cancer- and treatment-related anemia. Available from: http://www. nccn.org/professionals/physician-gls/PDF/anemia.pdf Accessed January 26, 2007.